References
- Antman KH, Schnipper LE, Frei E, III. The crisis in clinical cancer research: Third-party insurance and investigational therapy. N Engl J Med 1988; 319: 46–48
- Report of a study, Resources for Clinical Investigation. Institute of Medicine. 1988; 7–8
- McCabe M, Friedman MA. Letter. Impact of third-party reinbursement on cancer clinical investigation: A consensua statement coordinated by the National Cancer Institute. J Natl Cancer Inst 1989; 31: 1585–1586
- Remedies and costs of difficulties hampering clinical research. National Institutes of Health 1989; 9: 9
- Final report, National Committee to Review Current Procedures for Approval of New Drugs for Cancer and AIDS. August 15, 1990
- Report of the Council on Scientific Affairs. Report F (1-89). American Medical Association
- Proposed rule: New drug. antibiotic, and biological drug product regulations; accelerated approval. 57. Fed. Reg. April 15, 1992; 13: 234–242
- Friedman MA, McCabe MS. Commentary. Assigning care costs associated with therapeutic oncology research: A modest proposal. J Natl Cancer Inst 1992; 84: 760–763